Breaking

Two enforcement actions just hit the wire — a Schedule 13G on a pharma SPAC and a Fed action against a bank employee — and in this market, regulatory filings reprice positions before most people finish reading the headline.

First: Drugs Made In America Acquisition Corp. — ticker watch required. A Schedule 13G just landed on EDGAR from a significant stakeholder. 13G means passive holder, five percent or more. That's a position disclosure. If intent shifts to active, you'll see a 13D amendment — and that's when things get interesting. SPAC structures layer in extra complexity here: know your redemption windows before you react.

Second: The Federal Reserve just issued an enforcement action against a named employee of Bank of Eufaula and its parent, SNB Bancshares, Inc. Individual-level Fed actions are rare. They don't happen over paperwork. They happen when direct misconduct is found and documented. SNB Bancshares is private — no ticker — but if you're carrying regional bank exposure in your book, this is the kind of headline you cross-reference, not ignore.

Two stories. Both regulatory. Both dated June 25th to 26th, 2026. The bot flagged them. We're calling them. Regulatory risk doesn't wait for the broader market to catch up.

Numbers don't lie. People do. Trade accordingly.